Xuefeng Zang1, Chunyan Qian1, Ye Ruan2, Junwen Xie1, Ting Luo1, Bin Xu1,3, Jingting Jiang1,3. 1. Department of Clinical Trials Research Center, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province 213000, PR China. 2. Department of Oncology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province 213000, PR China. 3. Jiangsu Engineering Research Center for Tumor Immunotherapy, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province 213000, PR China.
Abstract
Aim: To elucidate potential prognostic significance of MELK mRNA expression in non-small-cell lung carcinoma patients. Methods: A loop algorithm based on R software was used to select genes with the best prognostic value. Mantel-Haenszel method and functional enrichment analysis were used to perform this analysis. Results: MELK mRNA expression level in tumor tissue is significantly higher than that in normal/benign tissue (p < 0.001), and gradually increases from stage I to IV (lung adenocarcinoma: p = 0.011; lung squamous cell carcinoma: p = 0.002), and is negatively correlated with prognosis in lung adenocarcinoma patients (HR: 2.025 in univariate analysis; HR: 2.162 in multivariate analysis). However, it does not show a significant correlation in lung squamous cell carcinoma patients. Conclusion: MELK is a poor biomarker for non-small-cell lung carcinoma patients and can potentially be used as a therapeutic target.
Aim: To elucidate potential prognostic significance of MELK mRNA expression in non-small-cell lung carcinomapatients. Methods: A loop algorithm based on R software was used to select genes with the best prognostic value. Mantel-Haenszel method and functional enrichment analysis were used to perform this analysis. Results:MELK mRNA expression level in tumor tissue is significantly higher than that in normal/benign tissue (p < 0.001), and gradually increases from stage I to IV (lung adenocarcinoma: p = 0.011; lung squamous cell carcinoma: p = 0.002), and is negatively correlated with prognosis in lung adenocarcinomapatients (HR: 2.025 in univariate analysis; HR: 2.162 in multivariate analysis). However, it does not show a significant correlation in lung squamous cell carcinomapatients. Conclusion:MELK is a poor biomarker for non-small-cell lung carcinomapatients and can potentially be used as a therapeutic target.